Status:
COMPLETED
Adipose Tissue and Immune Activation in HIV
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Human Immunodeficiency Virus
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
The prevalence of HIV-associated wasting declined dramatically with the introduction of effective antiretroviral therapy (ART), but as patients survive longer on treatment the proportion of overweight...
Detailed Description
HIV-infected individuals on long-term ART treatment are at increased risk for many diseases, particularly diabetes mellitus and coronary artery disease, which are more commonly associated with obesity...
Eligibility Criteria
Inclusion
- HIV-infected participants:
- age \>18 years
- on ART \>2 years
- a CD4+ nadir \>100 cells/µl prior to starting ART
- a CD4 \>350 cells/µl at the time of enrollment
- HIV-1 viral load \<50 copies/ml
- Pre-menopausal
Exclusion
- Pregnant (women only)
- Current use of anti-diabetic medications or statins
- HIV uninfected participants:
- Inclusion Criteria:
- age \>18 years
- body mass index \>= 30 kg/m2
- Pre-menopausal
Key Trial Info
Start Date :
April 12 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04439448
Start Date
April 12 2013
End Date
February 15 2020
Last Update
June 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232